We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
In This Issue of JAMA Ophthalmology |

Highlights FREE

JAMA Ophthalmol. 2016;134(2):121. doi:10.1001/jamaophthalmol.2015.3214.
Text Size: A A A
Published online


Because baseline visual acuity (VA) or baseline central subfield thickness (CST) from optical coherence tomography has an effect on the VA outcome comparisons of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema with vision loss, Wells and colleagues from the Diabetic Retinopathy Clinical Research Network provide a post hoc exploratory analysis based on both baseline VA and CST. In the subgroup with better baseline VA and thicker baseline CST, there was a suggestion of worse VA outcomes in the bevacizumab group. Given the exploratory nature of these analyses, caution is suggested when using the data to guide treatment for patients.

Interventions to improve glycemic control through early intensive treatment of diabetes reduce rates of severe retinopathy and preserve visual acuity. Gubitosi-Klug and colleagues for the Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group evaluate these effects on patient-reported vision-related function. A total of 1184 participants with type 1 diabetes completed the 25-item National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) during EDIC years 17 through 20. After adjustment for sex, age, hemoglobin A1c level, and retinopathy level at DCCT baseline, the former intensive treatment group had a significant, albeit modest, improvement in overall NEI-VFQ-25 score compared with the former conventional diabetes treatment group. In this cohort, patient-reported visual function remains high in both treatment groups.

Kinast and colleagues determine how measured concentration differs from the expected concentration of 0.4 mg/mL of mitomycin C (MMC) used in ophthalmic surgery. Among 60 samples acquired from a spectrum of common compounding (repackaging) and storage techniques and a variety of pharmacies, the measured MMC concentration determined using high-performance liquid chromatography was 12.5% lower than the expected 0.4 mg/mL value. The results suggest that variability in MMC concentration could cause inconsistency in glaucoma surgical results.

To understand how patients with glaucoma were affected by implementation of Medicare Part D, Blumberg and colleagues determine changes in prescription drug coverage and out-of-pocket spending after Medicare Part D across income strata, identifying characteristics of beneficiaries associated with prescription status. Using Medicare Current Beneficiary Survey data among 19 045 glaucoma prescriptions from 2519 Medicare beneficiaries with at least 1 filled glaucoma prescription, Medicare Part D resulted in increased rates of prescription drug coverage across all economic strata, with reductions in beneficiaries without coverage from 22.8% to 4.0%, 29.1% to 7.3%, and 19.9% to 3.7% among poor, near-poor, and higher-income beneficiaries, respectively. Near-poor status remained a risk factor for lack of prescription drug coverage after the implementation of Medicare Part D.

Journal Club





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Related Content

Customize your page view by dragging & repositioning the boxes below.